NEW YORK, March 5, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Immunomedics (NASDAQ: IMMU), Nymox (NASDAQ: NYMX), Meridian (NASDAQ: VIVO), Myriad (NASDAQ: MYGN), and Neogen (NASDAQ: NEOG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
IMMU Research Report: ( http://get.analystsreview.com/pdf/?c=Immunomedics&d=05-Mar-2015&s=IMMU ),
NYMX Research Report: ( http://get.analystsreview.com/pdf/?c=Nymox&d=05-Mar-2015&s=NYMX ),
VIVO Research Report: ( http://get.analystsreview.com/pdf/?c=Meridian&d=05-Mar-2015&s=VIVO ),
MYGN Research Report: ( http://get.analystsreview.com/pdf/?c=Myriad&d=05-Mar-2015&s=MYGN ),
NEOG Research Report: ( http://get.analystsreview.com/pdf/?c=Neogen&d=05-Mar-2015&s=NEOG ).
============
--
Analyst Update: Positive Trial Results, Debt Financing, Quarterly Results, Share Repurchase Programs, and Launches
Reviewed by: Rohit Tuli, CFA®
The U.S. indices fell for a second straight day as investors eye private-sector employment gains and await other jobs data. A pre-opening bell report from payroll processor ADP, showed that private employers hired 212,000 workers in February, slightly below the 218,000 new jobs economists were expecting. The S&P 500 was down 9.25 points, or 0.44%, to 2,098.53 while the Dow Jones Industrial Average shed 106.47 points, or 0.58%, to 18,096.90, and Nasdaq closed 12.76 points or 0.26% lower to end the session at 4,967.14. European stocks closed higher, with export-oriented stocks getting a boost following a sharp decline in the euro to an 11-1/2-year low against the dollar after the Institute for Supply Management said its services index rose to 56.9 in February against 56.5 predicted in a Reuters poll. The Euro STOXX 50 ended the day 0.97% higher to 3,583.44 while CAC 40 gained 0.99%, to close at 4,917.35. Mainland China share market closed higher in volatile trade after the HSBC Markit survey showed activity in China's service sector grew modestly in February. Japanese share market ended down, due to strengthening of yen against dollar and taking weak cues from Wall Street overnight.
Immunomedics, Inc. (Immunomedics) announced positive results of sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC) in treating small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The results of the multicenter study were presented at the 15th Annual Targeted Therapies of Lung Cancer Meeting, sponsored by The International Association for the Study of Lung Cancer.
Nymox Pharmaceutical Corporation (Nymox) announced the closure of $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53. The proceeds will be used as additional funding for the Company's activities in 2015.
Meridian Bioscience Inc. (Meridian) announced it Q1 FY 2015 financial results with record revenue of $48.0 million, up 7% YoY. Net earnings increased to $7.9 million or $0.19 per diluted share from $7.4 million or $0.18 per diluted share in Q1 FY 2014. The Company reaffirmed its fiscal 2015 guidance.
Myriad Genetics, Inc.'s (Myriad) Board of Directors has approved an additional $200 million authorization for its share repurchase program. As of the end of December 31, 2014, the Company has repurchased almost $1 billion of stock since the inception of the program in 2010.
Neogen Corporation (Neogen) has launched ANSR® for Listeria monocytogenes- the third test available for Neogen's innovative ANSR pathogen detection system, which provide results after only 10 minutes of reaction time following enrichment. The new test joins Neogen's line of ANSR products, which also includes AOAC Research Institute-validated ANSR for Listeria and ANSR for Salmonella.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
